FUNDAMENTALS · Fundamentals · JP Healthcare

Ain Holdings (9627) Fundamentals 2026 — P/E 11.9x, Revenue Analysis | SniperIQ

Ain Holdings (9627) is a JP-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥205.3B, trading at ¥5847.00 on the JPX. This SniperIQ fundamentals page covers Ain Holdings's valuation (P/E 11.9x, P/B 1.3x), profitability (net margin 2.7%), revenue (¥647.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥205.3B
P/E (TTM)11.9x
Net Margin2.7%
Revenue (FY25)¥647.8B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Ain Holdings's market cap?

Ain Holdings (9627) has a market capitalization of approximately ¥205.3B, trading at ¥5847.00 on the JPX. Market cap moves with the live share price.

What is Ain Holdings's P/E ratio?

Ain Holdings's trailing twelve-month P/E ratio is 11.9x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Ain Holdings?

Ain Holdings runs a net profit margin of 2.7%, a gross margin of 15.1%, and an operating margin of 5.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Ain Holdings generate?

Ain Holdings reported revenue of ¥647.8B for fiscal year 2025, with net income of ¥17.3B and earnings per share (EPS) of 491.6. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Ain Holdings pay a dividend?

Ain Holdings offers a trailing dividend yield of about 1.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Ain Holdings financially healthy?

Ain Holdings carries a debt-to-equity ratio of 1.08x and a current ratio of 0.94x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Ain Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ain Holdings (9627) the key facts are: market cap ¥205.3B, P/E 11.9x, revenue ¥647.8B, 52-week range 5313-7280. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Ain Holdings's full fundamentals live

Get Ain Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Towa Pharmaceutical (4553) fundamentals · BINEX (053030) fundamentals · Granules India (GRANULES) fundamentals · SMS (2175) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons